Recently, low-dose IL-2 has been clinically verified to ameliorate numerous autoimmune diseases, including type 1 diabetes, chronic graft versus host diseases and systemic lupus erythematosus (SLE)6–8. This evidence concerns the gene IL2 and systemic lupus erythematosus.